Welcome to

Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.

Learn More

Dinutuximab

Monoclonal Antibody

Brand names:

Unituxin®

Other names:

ch14.18, anti-GD2 antibody

Often used for:

Neuroblastoma

clipboard icon

About Dinutuximab

Dinutuximab is a type of monoclonal antibody. The medicine may be given in the clinic or in the hospital. It is administered by IV during a long infusion for multiple days in a row. Dinutuximab is usually used in combination with other medicines.

iv bag icon

May be given as a liquid into a vein by IV

 
exclamation mark in a circle icon

Possible Side Effects

  • Pain, which can be severe, or burning, tingling and numbness
  • Fever
  • Low blood pressure
  • Skin irritation, rash
  • Diarrhea
  • Loss of appetite
  • Nausea or vomiting
  • Swelling in face, lips, hands, ankles, or feet
  • Trouble breathing
  • Weight gain
  • Chest pain or pressure
  • Feeling of confusion

Not all patients who take dinutuximab will experience these side effects. Common side effects are in bold, but there may be others. Please report all suspected side effects to your doctor or pharmacist.

late effects icon

Possible Late Effects

Some patients may experience long-term or late effects of treatment that may continue or develop months or years after treatment ends. Dinutuximab is a relatively new medicine. At this time, there are no known late effects.

family icon

Tips for Families

Be sure to discuss these and other recommendations with your doctor or pharmacist.

  • Patients will receive IV fluids and medicines to help prevent reactions to dinutuximab. These include pain medications and antihistamines. The care team will watch the patient closely while the drug is infused and possibly for a couple of hours after the infusion ends.
  • This drug may cause a serious problem called capillary leak syndrome. It may lead to low blood pressure, an abnormal heartbeat, chest pain or pressure, heart attack, lung or breathing problems, bleeding problems, kidney problems, swelling, or feeling confused.
  • Sexually active patients should take steps to prevent pregnancy during treatment and for 6 months after completion of therapy.
  • Patients should tell their doctor if they are pregnant or breastfeeding.
  • Caregivers should follow instructions to avoid contact with patient body fluids, which can contain the drug for 48 hours after it is given.